BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 11756171)

  • 21. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation.
    Kamae T; Shiraga M; Kashiwagi H; Kato H; Tadokoro S; Kurata Y; Tomiyama Y; Kanakura Y
    J Thromb Haemost; 2006 Jun; 4(6):1379-87. PubMed ID: 16706985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.
    Ishii-Watabe A; Uchida E; Mizuguchi H; Hayakawa T
    Biochem Pharmacol; 2000 Jun; 59(11):1345-55. PubMed ID: 10751543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism.
    Kauffenstein G; Bergmeier W; Eckly A; Ohlmann P; Léon C; Cazenave JP; Nieswandt B; Gachet C
    FEBS Lett; 2001 Sep; 505(2):281-90. PubMed ID: 11566191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets.
    Liu J; Pestina TI; Berndt MC; Steward SA; Jackson CW; Gartner TK
    J Thromb Haemost; 2004 Dec; 2(12):2213-22. PubMed ID: 15613029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
    Shankar H; Garcia A; Prabhakar J; Kim S; Kunapuli SP
    J Thromb Haemost; 2006 Mar; 4(3):638-47. PubMed ID: 16460446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.
    Hechler B; Léon C; Vial C; Vigne P; Frelin C; Cazenave JP; Gachet C
    Blood; 1998 Jul; 92(1):152-9. PubMed ID: 9639511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation.
    Vigne P; Hechler B; Gachet C; Breittmayer JP; Frelin C
    Biochem Biophys Res Commun; 1999 Mar; 256(1):94-7. PubMed ID: 10066429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
    Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
    Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog.
    Chhatriwala M; Ravi RG; Patel RI; Boyer JL; Jacobson KA; Harden TK
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1038-43. PubMed ID: 15345752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P2 receptors and platelet activation.
    Kunapuli SP
    ScientificWorldJournal; 2002 Feb; 2():424-33. PubMed ID: 12806027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets.
    Nieswandt B; Schulte V; Zywietz A; Gratacap MP; Offermanns S
    J Biol Chem; 2002 Oct; 277(42):39493-8. PubMed ID: 12183468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation.
    Quinton TM; Kim S; Dangelmaier C; Dorsam RT; Jin J; Daniel JL; Kunapuli SP
    Biochem J; 2002 Dec; 368(Pt 2):535-43. PubMed ID: 12215172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation.
    Tseng YL; Chiang ML; Lane HY; Su KP; Lai YC
    Thromb Res; 2013 Apr; 131(4):325-32. PubMed ID: 23490430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G(12/13) signaling pathways substitute for integrin αIIbβ3-signaling for thromboxane generation in platelets.
    Bhavaraju K; Lakhani PR; Dorsam RT; Jin J; Hitchcock IS; Sanjay A; Kunapuli SP
    PLoS One; 2011 Feb; 6(2):e16586. PubMed ID: 21347357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors.
    Shattil SJ; Haimovich B; Cunningham M; Lipfert L; Parsons JT; Ginsberg MH; Brugge JS
    J Biol Chem; 1994 May; 269(20):14738-45. PubMed ID: 7514181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross talk between serine/threonine and tyrosine kinases regulates ADP-induced thromboxane generation in platelets.
    Bhavanasi D; Badolia R; Manne BK; Janapati S; Dangelmaier CT; Mazharian A; Jin J; Kim S; Zhang X; Chen X; Senis YA; Kunapuli SP
    Thromb Haemost; 2015 Aug; 114(3):558-68. PubMed ID: 25947062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators.
    Lau LF; Pumiglia K; Côté YP; Feinstein MB
    Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):391-400. PubMed ID: 7526841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
    Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.